FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4302024129> ?p ?o ?g. }

• W4302024129 endingPage "292" @default.
• W4302024129 startingPage "281" @default.
• W4302024129 abstract "Diabetes mellitus (DM) is known to increase the risk of hepatocellular carcinoma (HCC) among individuals with chronic hepatitis C (CHC). We aimed to evaluate whether metformin reduces HCC risk among individuals with DM and CHC after successful antiviral therapy.Individuals with CHC who achieved a sustained virological response (SVR) after interferon-based therapy were enrolled in a large-scale, multicenter cohort in Taiwan (T-COACH). Cases of HCC at least 1 year after SVR were identified through linkage to the catastrophic illness and cancer registry databases.Of 7,249 individuals with CHC enrolled in the study, 781 (10.8%) had diabetes and 647 (82.8%) were metformin users. During a median follow-up of 4.4 years, 227 patients developed new-onset HCC. The 5-year cumulative HCC incidence was 10.9% in non-metformin users and 2.6% in metformin users, compared to 3.0% in individuals without DM (adjusted hazard ratio [aHR] 2.83; 95% CI 1.57-5.08 and aHR 1.46; 95% CI 0.98-2.19, respectively). Cirrhosis was the most important factor significantly associated with higher HCC risk in Cox regression analysis, followed by DM non-metformin use, older age, male sex, and obesity; whereas hyperlipidemia with statin use was associated with a lower HCC risk. Using the two most crucial risk factors, cirrhosis and DM non-metformin use, we constructed a simple risk model that could predict HCC risk among individuals with CHC after SVR. Metformin use was shown to reduce the risk of all liver-related complications.Metformin use greatly reduced HCC risk after successful antiviral therapy in individuals with diabetes and CHC. A simple risk stratification model comprising cirrhosis and DM non-metformin use could predict long-term outcomes in individuals with CHC after SVR.The current study provides evidence that metformin could reduce hepatocellular carcinoma (HCC) incidence after successful antiviral therapy among those with diabetes and chronic hepatitis C in a large-scale nationwide cohort study. Although successful antiviral therapy greatly reduces HCC risk in individuals with chronic hepatitis C, those with cirrhosis, diabetes, obesity, and the elderly remain at high risk of HCC development. We demonstrated that a simple risk model composed of two crucial unfavorable factors, cirrhosis and diabetes without metformin use, predicts the risk of HCC and major liver-related complications after successful antiviral therapy in individuals with chronic hepatitis C. Metformin use is highly recommended for individuals with diabetes and chronic hepatitis C after viral eradication to reduce the risk of HCC." @default.
• W4302024129 created "2022-10-06" @default.
• W4302024129 creator A5006299777 @default.
• W4302024129 creator A5006428879 @default.
• W4302024129 creator A5008410960 @default.
• W4302024129 creator A5009330208 @default.
• W4302024129 creator A5014821725 @default.
• W4302024129 creator A5014979821 @default.
• W4302024129 creator A5016683607 @default.
• W4302024129 creator A5027422393 @default.
• W4302024129 creator A5032481034 @default.
• W4302024129 creator A5035460520 @default.
• W4302024129 creator A5037536297 @default.
• W4302024129 creator A5039672232 @default.
• W4302024129 creator A5040415788 @default.
• W4302024129 creator A5041151016 @default.
• W4302024129 creator A5043777518 @default.
• W4302024129 creator A5043780319 @default.
• W4302024129 creator A5045439912 @default.
• W4302024129 creator A5045897198 @default.
• W4302024129 creator A5046862705 @default.
• W4302024129 creator A5047952456 @default.
• W4302024129 creator A5048460639 @default.
• W4302024129 creator A5049658299 @default.
• W4302024129 creator A5057043300 @default.
• W4302024129 creator A5057490544 @default.
• W4302024129 creator A5057578521 @default.
• W4302024129 creator A5061322757 @default.
• W4302024129 creator A5061982402 @default.
• W4302024129 creator A5062313199 @default.
• W4302024129 creator A5062373695 @default.
• W4302024129 creator A5068024272 @default.
• W4302024129 creator A5069854148 @default.
• W4302024129 creator A5071784319 @default.
• W4302024129 creator A5072593323 @default.
• W4302024129 creator A5075846648 @default.
• W4302024129 creator A5078744722 @default.
• W4302024129 creator A5084736983 @default.
• W4302024129 creator A5085096104 @default.
• W4302024129 creator A5089722538 @default.
• W4302024129 creator A5090245512 @default.
• W4302024129 creator A5090991069 @default.
• W4302024129 date "2023-02-01" @default.
• W4302024129 modified "2023-10-18" @default.
• W4302024129 title "Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan" @default.
• W4302024129 cites W1728809351 @default.
• W4302024129 cites W2004791698 @default.
• W4302024129 cites W2010292892 @default.
• W4302024129 cites W2011346803 @default.
• W4302024129 cites W2014666790 @default.
• W4302024129 cites W2027498662 @default.
• W4302024129 cites W2036193982 @default.
• W4302024129 cites W2038981426 @default.
• W4302024129 cites W2039465862 @default.
• W4302024129 cites W2059201072 @default.
• W4302024129 cites W2064387090 @default.
• W4302024129 cites W2073140442 @default.
• W4302024129 cites W2088849513 @default.
• W4302024129 cites W2102829643 @default.
• W4302024129 cites W2139024781 @default.
• W4302024129 cites W2155510029 @default.
• W4302024129 cites W2158373383 @default.
• W4302024129 cites W2277004004 @default.
• W4302024129 cites W2465608032 @default.
• W4302024129 cites W2470529413 @default.
• W4302024129 cites W2473403355 @default.
• W4302024129 cites W2583273198 @default.
• W4302024129 cites W2742220140 @default.
• W4302024129 cites W2761031851 @default.
• W4302024129 cites W2776129033 @default.
• W4302024129 cites W2900453721 @default.
• W4302024129 cites W2937135846 @default.
• W4302024129 cites W2941033601 @default.
• W4302024129 cites W2949406476 @default.
• W4302024129 cites W2950514720 @default.
• W4302024129 cites W2991283674 @default.
• W4302024129 cites W2995166528 @default.
• W4302024129 cites W2999097687 @default.
• W4302024129 cites W3013889062 @default.
• W4302024129 cites W3014083469 @default.
• W4302024129 cites W3041840532 @default.
• W4302024129 cites W3081830084 @default.
• W4302024129 cites W3088534142 @default.
• W4302024129 cites W3091564728 @default.
• W4302024129 cites W3119519530 @default.
• W4302024129 cites W3130947991 @default.
• W4302024129 cites W3133542224 @default.
• W4302024129 cites W3158331478 @default.
• W4302024129 cites W3207903479 @default.
• W4302024129 cites W3212896804 @default.
• W4302024129 doi "https://doi.org/10.1016/j.jhep.2022.09.019" @default.
• W4302024129 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36208843" @default.
• W4302024129 hasPublicationYear "2023" @default.
• W4302024129 type Work @default.
• W4302024129 citedByCount "12" @default.
• W4302024129 countsByYear W43020241292023 @default.
• W4302024129 crossrefType "journal-article" @default.
• W4302024129 hasAuthorship W4302024129A5006299777 @default.

• next